New Lilly data suggest Zepbound boosted effect of autoimmune drug
New Phase 3b data from Eli Lilly suggest that its blockbuster weight loss drug helped boost the efficacy of an autoimmune treatment in select patients with active psoriatic arthritis who were overweight or obese. …
Is LLY’s Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic health remains its core focus, LLY is deliberately broadening its footprint into other therapeutic areas, such as oncology, neuroscience, ophthalmology, and immunology, through targeted deals. Eli Lilly […]
Former GLP-1 users regain lost weight after about 18 months, study says – The Washington Post
Former GLP-1 users regain lost weight after about 18 months, study says The Washington Post People Who Stop Taking Weight-Loss Medications Regain Weight Within 2 Years, Study Says People.com Less than two years after stopping obesity drugs, weight and health issues return, study finds Reuters Obesity drug users will regain weight two years after ending medication, review finds Financial […]
The 20 most influential drug approvals of 2025: GoodRx
GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect public health. 1. Nereus (tradipitant) for motion sickness: Approved Dec. 30, Nereus is the first new prescription drug in decades for motion sickness. The oral capsule works […]
GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter published online Dec. 29 in JAMA Network Open.
GLP-1 Market Trends and Global Forecasts 2025-2035: 150+ Candidates Intended for the Treatment of Multiple Indications, are Currently Either Approved or Being Investigated – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “GLP-1 Market: Industry Trends and Global Forecasts, Till 2035” report has been added to ResearchAndMarkets.com’s offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period, till 2035. The efficacy of GLP-1 […]
Weight loss drugs are effective, but can healthcare systems afford them?
The use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for weight loss is increasing rapidly, with an estimated one in 50 adults in the UK using these treatments to help manage their weight.1 These drugs have been licensed based on trials that show a weight reduction of 15-20%, along with improvements in obesity related comorbidities.23 […]
I lost 8st on weight-loss jabs – but I am devastated by the aftermath
New data published in the British Medical Journal suggests overweight people shed large amounts when they take weight-loss drugs, but once they quit they regain it within 20 months of stopping the injections – four times faster than traditional dieters. “People buying these need to be aware of the risk of fast weight regain when […]
Novo Nordisk quietly loses key Washington insider amid pricing war
Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo said that Jennifer Duck, who was in charge of U.S. public affairs for Novo Nordisk, left the business on Jan. 5, Reuters reported. The developer of Wegovy and Ozempic is trying […]
Former GLP-1 users regain lost weight after about 18 months, study says
Those quitting Ozempic, Wegovy and other drugs regained weight four times faster than those using just diet and exercise, still key components in weight maintenance.